 Trem-cel formerly VOR33 successfully manufactured and engrafted normally Blood counts successfully maintained following post-transplant treatment with Mylotarg Conference call scheduled for today, December 7 at 8:00am ET CAMBRIDGE, Mass., Dec. 07, 2022 GLOBE NEWSWIRE Vor Bio Nasdaq: VOR, a clinical-stage cell and genome engineering company, today announced initial clinical data from VBP101, its Phase ... The post First AML Patient Successfully Transplanted with Vor Bios Investigational... 